SOURCE-LINKED STUDY SUMMARY
In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.
Full paper summarizedQuality not appraised
- What was studied
- Randomized, double-blind trial of a single elamipretide infusion on hand-muscle mitochondrial ATP capacity and fatigue resistance.
- Who / model studied
- 39 adults aged 60–85 with low mitochondrial function; findings do not establish benefits in healthy young athletes.
- Studied dose & schedule
- Elamipretide intravenously at 0.25 mg/kg/hour for 2 hours versus vehicle placebo; follow-up through day 7.
- What the study found
- ATP capacity rose 27% versus 12% immediately after infusion. Relative change differed (P=0.045); absolute change did not reach significance (P=0.055). No between-group ATP difference remained at day 7; prespecified fatigue resistance did not improve.
- Limitations & context
- Small study with missing measurements and exploratory secondary analyses; no durable functional benefit established. Detailed adverse-event results were not provided in the assessed main text.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1371/journal.pone.0253849